Perifosine inhibits growth of rapamycin resistant cells through activating GSK3β

Abstract

Abstract: AIM: To investigate the effects and mechanisms of perifosine on the growth of rapamcyin resistant NSCLC cells. METHODS: The growth inhibitory effects of perfisoine with or without LiCl on NSCLC cells were detected by SRB assay. The regulatory effects of perifosine on Akt, GSK3β singaling were detected by Western blotting. RESULTS: Perifosine had similar inhibitory effects on the growth of rapamycin resistant and sensitive cells. Perifosine inhibited phosphorylation of GSK3β without significant alteration of Akt phosphorylation, and thus activated GSK3β in rapamycin resistant cells. The inhibitor of GSK3β- LiCl blocked perifosine's inhibitory effects on the growth of rapamycin resistant cells. CONCLUSION: Perifosine inhibits growth of rapamycin resistant NSCLC cells through activating GSK3β.

Key words: Drug resistance, GSK3β, Rapamycin, Perifosine

CLC Number:

R965.2

DONG Guang-hui, LUO Xuan, ZHAI Su-lan, LI Ping, WANG Xue-rong. Perifosine inhibits growth of rapamycin resistant cells through activating GSK3β[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(4): 389-392.

References

[1] 李婧婧, 冯公侃, 朱孝峰,等. 西妥昔单抗联合顺铂对鼻咽癌荷瘤裸鼠移植瘤生长作用的影响[J].中国临床药理学与治疗学, 2008, 13(7):735-739.
[2] Wang X, Yue P, Kim YA, et al. Enhancing mammalian target of Rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation [J].Cancer Res,2008,68(18): 7409-7418.
[3] Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor[J].Curr Oncol Rep,2009,11(2): 102-110.
[4] LoPiccolo J, Blumenthal GM, Bernstein WB, et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations[J].Drug Resist Updat,2008,11(1/2): 32-50.
[5] 周星辉, 王丙力, 谭焕然,等.大鼠肝实质细胞原代培养模型的研究及其功能鉴定[J].中国临床药理学与治疗学,2005, 10(7):743-746.
[6] Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression[J].Cell Cycle,2003,2(4): 339-345.
[7] Wang X, Sun SY. Enhancing mTOR-targeted cancer therapy[J].Expert Opin Ther Targets,2009,13(10): 1193-1203.
[8] Fu L, Kim YA, Wang X, et al. Perifosine inhibits mammalian target of Rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy[J].Cancer Res,2009,69(23): 8967-8976.
[9] Xu C, Kim NG, Gumbiner BM. Regulation of protein stability by GSK3 mediated phosphorylation[J].Cell Cycle,2009,8(24): 4032-4039.
[10] Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer[J].J Clin Invest,2008,118(9): 3065-3074.
[11] Wang X, Hawk N, Yue P, et al. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy[J].Cancer Biol Ther,2008,7(12): 1952-1958.
[12] Wang X, Yue P, Chan CB, et al. Inhibition of mammalian target of Rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation[J].Mol Cell Biol,2007,27(21): 7405-7413.
[13] Abraham RT, Gibbons JJ. The mammalian target of Rapamycin signaling pathway: twists and turns in the road to cancer therapy[J].Clin Cancer Res,2007,13(11): 3109-3114.
[14] Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma[J].N Engl J Med,2007,356(22): 2271-2281.
[15] Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by Rapamycin-mediated mammalian target of Rapamycin inhibition[J].Cancer Res,2005,65(16): 7052-7058.